ArticleCancer2022
Improved survival of patients with myelofibrosis in the last decade: Single-center experience.
Article in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 40 citations in OpenAlex.
- Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis.Blood neoplasia · 2025Trial
- Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.British journal of haematology · 2026Article
- Article
- Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.Cancer · 2026Article
- Incidence, Prevalence, and Survival Outcomes of Patients with Myeloproliferative Neoplasms in the United States: a SEER database analysis, years 2000-2021.Research square · 2026Article
- Novel therapies in myeloid neoplasms show limited benefit and increased costs over 15 years of follow-up in Southern Finland.Annals of hematology · 2026Observational
- Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosis.HemaSphere · 2026Article
- Symptom severity clusters in myeloproliferative neoplasms are unrelated to disease phenotype: results from a multicenter survey of the East German study group for hematology and oncology (OSHO #97).Frontiers in oncology · 2026Article
- Fat Fraction MRI for Longitudinal Assessment of Bone Marrow Heterogeneity in a Mouse Model of Myelofibrosis.Tomography (Ann Arbor, Mich.) · 2025Article
- A comprehensive overview of patient journey and management decision pathway for myelofibrosis in India: INLAND survey.BMC cancer · 2025Article
- Assessing myelofibrosis burden on QoL and productivity from healthcare personnel and patient perspectives in India.BMC cancer · 2025Article
- Emerging Therapeutic Approaches for Anemia in Myelofibrosis.Current hematologic malignancy reports · 2025Review
- Article
- Survey of Clinical Practice in Chronic Myeloproliferative Neoplasms in Croatia: A Study by the MPN Working Group Party of the Croatian Cooperative Group for Hematologic Diseases (KROHEM).Journal of clinical medicine · 2025Article
- Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib.Future oncology (London, England) · 2025Article
- Prognostic Implications of Red Blood Cell Distribution Width to Albumin Ratio in Myelofibrosis: A 10-Year Multicenter and Retrospective Study.Journal of inflammation research · 2025Article
- A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.Science translational medicine · 2024Article
- Prognostic and Predictive Models in Myelofibrosis.Current hematologic malignancy reports · 2024Review
- Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications-A Narrative Review.Current issues in molecular biology · 2024Review
- Management of Patients with Early Myelofibrosis: A Discussion of Best Practices.Current hematologic malignancy reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe management of myelofibrosis (MF) has changed over the last several years and could have an impact on patient outcome. This study evaluates the survival of patients with MF at the authors' institution to determine whether it changed in the last decade.
methodsThis retrospective study consists of 844 patients (64% male; median age, 66 years; range, 20-90 years) who were examined between 2000 and 2020 with a new diagnosis of MF. Only patients with available marrow biopsy who had reticulin fibrosis of grade 2 or higher were included. Patients were compared by year of presentation: 2000-2010 (n = 373) and 2011-2020 (n = 471).
resultsA statistically significant improvement in median survival in the last decade was noted: from 48 months (95% CI, 42-54 months) to 63 months (95% CI, 55-71 months) (P < .001; HR, 0.78 [95% CI, 0.64-0.95]). Improved survival was observed also in patients 65 years old or older and those having intermediate 2 or high-risk Dynamic International Prognostic Scoring System (DIPSS) or DIPSS-Plus risk scores. Among 532 patients treated with MF-directed therapy, patients exposed to JAK inhibitor ruxolitinib had superior outcomes with median overall survival of 84 months (95% CI, 70-94 months).
conclusionsThe results demonstrate that survival of patients with MF has improved in the last decade. This improvement is likely due to increased disease awareness, advances in supportive care, and the development of effective treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.